31 March 2014 - Deborah Wilkes
Archived
GlaxoSmithKline has acquired the 30% stake in its Indonesian Consumer Healthcare business that it did not previously own, and is divesting the Insto eye drops brand and a manufacturing facility in the country.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.